Differential response of cholesterol and particle measures of atherogenic lipoproteins to LDL-lowering therapy: implications for clinical practice

Journal of Clinical Lipidology

Volumn 2, Issue 1, 2008, Pages 36-42

  Sniderman, Allan D ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

LDL C; LDL P; Statin therapy

Indexed keywords

ANTILIPEMIC AGENT; APOLIPOPROTEIN B; ATORVASTATIN; CHOLESTEROL; EZETIMIBE; FLUINDOSTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CLINICAL PRACTICE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DRUG DOSE COMPARISON; DRUG TARGETING; HUMAN; MEDICAL RESEARCH; MONOTHERAPY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OUTCOME ASSESSMENT; PARTICLE SIZE; POPULATION RESEARCH; PRIORITY JOURNAL; RISK REDUCTION; TREATMENT OUTCOME;

EID: 39149125755     PISSN: 19332874     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacl.2007.12.006     Document Type: Article

References (40)

1. Marcovina S., and Packard C.J. Measurement and meaning of apolipoprotein AI and apolipoprotein B plasma levels. J Intern Med 259 (2006) 437-446
2. Dunbar R.L., and Rader D.J. Measurement of atherogenic lipoproteins in cardiovascular risk assessment. In: Morrow D.A. (Ed). Contemporary Cardiology: Cardiovascular Biomarkers: Pathophysiology and Disease Management (2006), Humana Press, Inc, Totowa, NJ 507-517
3. Barter P.J., Ballantyne C.M., Carmena R., et al. ApoB versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med 259 (2006) 247-258
4. Otvos J.D. Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. Clin Lab 48 (2002) 171-180
5. Sniderman A.D., Dagenais G.R., Cantin B., Despres J.P., and Lamarche B. High apolipoprotein B with low high-density lipoprotein cholesterol and normal plasma triglycerides and cholesterol. Am J Cardiol 87 (2001) 792-793 A8
6. Kim B.J., Hwang S.T., Sung K.C., et al. Comparison of the relationships between serum apolipoprotein B and serum lipid distributions. Clin Chem 51 (2005) 2257-2263
7. Sniderman A.D., Hogue J.C., Bergeron J., Gagne C., and Couture P. Non-HDL C and apoB in dyslipidemia. Clin Sci 114 (2008) 149-155
8. Adult Treatment Panel III. Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. JAMA 285 (2001) 2486-2497
9. Grundy S.M., Cleeman J.I., Merz C.N., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239
10. McPherson R., Frohlich J., Fodor G., Genest J., and Canadian Cardiovascular Society. Canadian Cardiovascular Society position statement-recommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease. Can J Cardiol 22 (2006) 913-927
11. Jeyarajah E.J., Cromwell W.C., and Otvos J.D. Lipoprotein particle analysis by nuclear magnetic resonance spectroscopy. Clin Lab Med 26 (2006) 847-870
12. Nissen S.E., Nicholls S.J., Sipahi I., et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis. The ASTEROID Trial. JAMA 295 (2006) 1556-1565
13. Nissen S.E., Tuzcu E.M., Schoenhagen P., et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA 291 (2004) 1071-1080
14. Gotto A.M., Whitney E., Stein E.A., Shapiro D.R., Clearfield M., and Weis S. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Circulation 101 (2000) 477-484
15. Roeters van Lennep J.E., Westerveld H.T., Roeters van Lennep H.W.O., Zwinderman A.H., Erkelens D.W., and van der Wall E.E. Apolipoprotein concentrations during treatment and recurrent coronary artery disease events. Arterioscler Thromb Vasc Biol 20 (2000) 2408-2413
16. Simes R.J., Marschner I.C., Hunt D., Colquhoun D., Sullivan D., and Stewart R.A.H. Relationship between lipid levels and clinical outcomes in the long-term intervention with pravastatin in the ischemic disease (LIPID) trial. To what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels?. Circulation 105 (2002) 1162-1169
17. Colhoun H.M., Betteridge D.J., Durrington P.N., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364 (2004) 685-696
18. Ballantyne C.M., Andrews T.C., Hsia J.A., Kramer J.H., and Shear C. Correlation of non-high-density lipoprotein cholesterol with apolipoprotein B: effect of 5 hydroxymethylglutaryl coenzyme A reductase inhibitors on non-high-density lipoprotein cholesterol levels. Am J Cardiol 88 (2001) 265-269
19. Ballantyne C.M., Bertolami M.C., Hernandez-Garcia H.R., et al. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: measuring effective reductions in cholesterol using rosuvastatin therapy (MERCURY) II. Am Heart J 151 (2006) 975-983
20. Ballantyne C.M., Weiss R., Moccetti T., et al. Efficacy and safety of Rosuvastatin 40 mg alone or in combination with Ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER Study. Am J Cardiol 99 (2007) 673-680
21. Bays H.E., Dujovne C.A., McGovern M.E., White T.E., Kashyap M.L., Hutcheson A.G., and Crouse J.R. Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (The Advicor Versus Other Cholesterol-Modulating Agents Trial Evaluation. [ADVOCATE]. Am J Cardiol 91 (2003) 667-672
22. McKenney J.M., Jones P.H., Bays H.E., et al. Comparative effects on lipid levels of combination therapy with a statin and extended-release niacin or exetimbe versus a statin alone (the COMPELL study). Atherosclerosis 192 (2007) 432-437
23. Miller M., Dolinar C., Cromwell W., and Otvos J.D. Effectiveness of high doses of simvastatin as monotherapy in mixed hyperlipidemia. Am J Cardiol 87 (2001) 232-234
24. McKenney J.M., McCormick L.S., Weiss S., Koren M., Kafonek S., Black D.M., and Collaborative Atorvastatin Study Group. A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Am J Med 104 (1998) 137-143
25. Rosenson R.S., Shalaurova I., Freedman D.S., and Otvos J.D. Effects of pravastatin treatment on lipoprotein subclass profiles and particle size in the PLAC-I trial. Atherosclerosis 160 (2002) 41-48
26. Blake G.J., Albert M.A., Rifai N., and Ridker P.M. Effect of pravastatin on LDL particle concentration as determined by NMR spectroscopy: a substudy of a randomized placebo controlled trial. Eur Heart J 24 (2003) 1843-1847
27. Soedamah S.S., Colhoun H.M., Thomason M.J., et al. The effect of atorvastatin on serum lipids, lipoproteins and NMR spectroscopy defined lipoprotein subclasses in type 2 diabetic patients with ischemic heart disease. Atherosclerosis 167 (2003) 243-255
28. Schaefer E.J., McNamara J.R., Tayler T., et al. Comparisons of effects of statins (atorvastatin, fluvastatin, lovastatin, pravastatin, and simvastatin) on fasting and postprandial lipoproteins in patients with coronary heart disease versus control subjects. Am J Cardiol 93 (2004) 31-39
29. Stein J.H., Merwood M.A., Bellehumeur J.L., et al. Effects of pravastatin on lipoproteins and endothelial function in patients receiving human immunodeficiency virus protease inhibitors. Am Heart J 147 (2004) E18
30. Contois J.H., McNamara J.R., Lammi-Keefe C.J., Wilson P.W., Massov T., and Schaefer E.J. Reference intervals for plasma apolipoprotein B determined with a standardized commercial immunoturbidimetric assay: results from the Framingham Offspring Study. Clin Chem 42 (1996) 515-523
31. National Cholesterol Education Program. Risk assessment tool for estimating your 10-year risk of having a heart attack. http://hinnhlbinihgov/atpiii/calculator asp Accessed September 18, 2007
32. Nutrition Examination Survey III. Data set. http://www.cdc.gov/nchs/nhanes.htm Accessed September 18, 2007
33. Marcovina S.M., Albers J.J., Kennedy H., Mei J.V., Henderson L.O., and Hannon W.H. International Federation of Clinical Chemistry standardization project for measurements of apolipoproteins A-I and B. IV. Comparability of apolipoprotein B values by use of International Reference Material. Clin Chem 40 (1994) 586-592
34. Connelly P.W., Poapst M., Davignon J., et al., Canadian Heart Health Surveys Research Group. Reference values of plasma apolipoproteins A-I and B, and association with nonlipid risk factors in the populations of two Canadian provinces: Quebec and Saskatchewan. Can J Cardiol 15 (1999) 409-418
35. Cromwell W.C., Otvos J.D., Keyes M.J., et al. LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study-implications for LDL management. J Clin Lipidol 1 (2007) 583-592
36. Sniderman A.D., Zhang X., and Cianflone K. Governance of the concentration of plasma LDL: a reevaluation of the LDL receptor paradigm. Atherosclerosis 148 (1999) 215-229
37. Guerin M., Lassel T.S., Le Goff W., Farnier M.A., and Chapman M.J. Action of atorvastatin in combined hyperlipidemia: preferential reduction of cholesteryl ester transfer from HDL to VLDL1 particles. Arterioscler Thromb Vasc Biol 20 (2000) 189-197
38. Otvos J.D., Jeyarajah E.J., and Cromwell W.C. Measurement issues related to lipoprotein heterogeneity. Am J Cardiol 90 (2002) 22-29
39. Stein E.A., Sniderman A., and Laskarzewski P. Assessment of reaching goal in patients with combined hyperlipidemia: low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, or apolipoprotein B. Am J Cardiol 96 (2005) 36-43
40. Mudd J.O., Boriaug B.A., Johnston P.V., et al. Beyond low-density lipoprotein cholesterol: defining the role of low-density lipoprotein heterogeneity in coronary artery disease. J Am Coll Cardiol 50 (2007) 1735-1741